Tegretol-XR Side Effects

Please note - some side effects for Tegretol-XR may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects by Body System - for Healthcare Professionals

Gastrointestinal

Gastrointestinal side effects have included nausea, vomiting, dry mouth, diarrhea, constipation, and oral ulceration.

A single case of chemical pancreatitis has been reported in association with carbamazepine intoxication.

Endocrine

Carbamazepine increases the rate of T4 and T3 metabolism and may lead to hypothyroidism in patients with hypothyroidism who are being treated with T4. Carbamazepine may also cause a 20% to 40% decrease in serum total and free T4 concentrations and a smaller decrease in serum total and free T3 concentrations in patients who have no thyroid disease.

Chronic administration of carbamazepine may increase total cholesterol and HDL cholesterol levels. Carbamazepine may also transiently increase serum triglyceride and LDL cholesterol levels. One study has suggested that demeclocycline may be useful in prophylaxis of carbamazepine-induced hyponatremia.

Endocrine side effects including hyponatremia have been observed frequently and represent the most common laboratory abnormality during carbamazepine therapy. Hyponatremia is occasionally severe enough to require discontinuation of carbamazepine.

Carbamazepine has been associated with lower serum testosterone and lower free androgen indexes.

One study has suggested that carbamazepine may decrease serum levels of T4, FT4, and T3. In that study, TSH concentrations were not significantly altered. Additionally, carbamazepine may exert adverse effects on serum lipids.

A study of nine patients reported that carbamazepine increased cerebrospinal fluid thyrotropin-releasing hormone levels.

Hematologic

Hematologic side effects including leukopenia, neutropenia, and thrombocytopenia have been reported in approximately 2% of patients. These reactions may require discontinuation of carbamazepine. Some clinicians recommend monitoring complete blood counts during carbamazepine therapy at baseline, then weekly for two months, then every three months.

Thrombocytopenia is the most common hematologic effect of carbamazepine and may be either mild and transient or severe. Significant decreases in white blood cell counts may occur although the values may still be within the normal range. Often counts will return to baseline during continued therapy, and therefore, discontinuation of carbamazepine may not be necessary. Dose reductions may also result in normalization of white blood cell counts. Aplastic anemia has been reported (although many of the reported cases had confounding exposures to other medications). The manufacturer reports an incidence of 2 per 1,000,000 patients for aplastic anemia and 6 per 1,000,000 patients for agranulocytosis. Cases of reticulocytosis have been reported rarely in association with carbamazepine therapy as well. In addition, cases of hemolytic anemia and erythroid arrest have been reported.

Both humoral and nonimmune mechanisms have been implicated in the etiology of carbamazepine-induced bone marrow suppression.

Cardiovascular

Cardiovascular side effects including various forms of heart block, hypotension and electrocardiographic changes have been reported. One study has reported that abrupt withdrawal of carbamazepine leads to enhanced sympathetic activity in sleep. A case of cardiac tamponade as a severe manifestation due to a carbamazepine induced systemic lupus erythematosus-like syndrome has also been reported.

Most of the cases of cardiovascular effects reported have occurred in patients receiving carbamazepine for trigeminal neuralgia. The reported effects included congestive heart failure, edema, hypotension, syncope and arrhythmias. In general, the doses were titrated quickly because of severe pain. Many of the doses were higher than those used to treat epilepsy. Many of the reported cardiovascular effects resolved after discontinuation of carbamazepine.

Increased sympathetic activity in the setting of seizure-induced hypoxia could predispose a patient to sudden unexpected death in epilepsy (SUDEP).

Nervous system

Rigidity and oculogyric crises have been reported. Euphoria has also been reported and has led to abuse of carbamazepine in some patients. Impairment of psychomotor function has been noted in association with use of the liquid suspension of carbamazepine. Additionally, impaired cognition, exacerbations of focal seizures and asterixis have been reported in association with carbamazepine treatment. One case of a lingual-facial-buccal extrapyramidal reaction has also been described.

One study has suggested that gradual withdrawal of carbamazepine over ten days results in significantly fewer generalized tonic-clonic seizures compared to rapid withdrawal over four days.

One study has suggested that the epoxide metabolite of carbamazepine may be responsible for the occasional occurrence of seizure exacerbations in patients receiving carbamazepine.

Nervous system side effects have included drowsiness, dizziness, confusion, headache, ataxia, blurred vision, nystagmus and speech disturbances. (These effects appear to be more common at higher carbamazepine concentrations.)

Hypersensitivity

Hypersensitivity side effects including pruritus, erythematous, and urticarial rashes have been reported. Two cases of a lupus-like syndrome, one case of pneumonitis, and one case of hypersensitivity syndrome have been reported. A case of hypersensitivity reaction consisting of eosinophilia and systemic symptoms syndrome has also been reported.

Rash and pruritus often resolve after discontinuation of carbamazepine therapy. Both cases of lupus-like syndrome resolved after discontinuation of carbamazepine. Stevens-Johnson syndrome, erythema multiforme, and a mononucleosis-like syndrome have also been reported.

Hepatic

Alterations in liver function tests may progress to hepatotoxicity including cholangitis, granuloma formation, fever and hepatocellular necrosis. Discontinuation of carbamazepine often results in improvement in laboratory abnormalities and liver injury.

Hepatic side effects including liver function test abnormalities have been reported during carbamazepine therapy. These abnormalities may progress to hepatotoxicity. Some clinicians recommend monitoring liver function tests during carbamazepine therapy at baseline, then every three months.

Renal

Renal side effects including cases of acute renal failure and acute tubulointerstitial nephritis have been associated with carbamazepine therapy.

Respiratory

Respiratory side effects including a case of pulmonary interstitial pneumonitis has been reported in association with carbamazepine therapy.

Dermatologic

Dangerous, sometimes fatal skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis), that can be caused by carbamazepine therapy are significantly more common in patients with the human leukocyte antigen (HLA) allele, HLA-B 1502. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians. Patients with ancestry from areas in which HLA-B 1502 is present should be screened for the HLA-B 1502 allele before starting treatment with carbamazepine. If these individuals test positive, carbamazepine should not be started unless the expected benefit clearly outweighs the increased risk of serious skin reactions. Patients who have been taking carbamazepine for more than a few months without developing skin reactions are at low risk of these events ever developing from carbamazepine. This is true for patients of any ethnicity or genotype, including patients who test positive for HLA-B 1502.

Dermatologic side effects including Stevens Johnson syndrome and toxic epidermal necrolysis, alopecia (0.01%), photosensitivity, and unusual bruising have been reported. A case of psoriasiform eruption has also been reported in a patient receiving carbamazepine.

Ocular

Ocular side effects include a mild overall impairment of the chromatic and achromatic systems according to one study on color visualization following a single dose.

Oncologic

Oncologic side effects including a case of large-cell lymphoma have been reported.

Immunologic

Immunologic side effects including a case of antibody deficiency associated with carbamazepine has been reported.

Psychiatric

Psychiatric side effects including a case of rebound mania following discontinuation of carbamazepine have been reported.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.